#San Jose #Costa Rica #SteinCares #Biosimilars #Shilpa Biologicals

Strategic Partnership for Biosimilars

In an innovative move to enhance medical care across Latin America, SteinCares, a prominent leader in the healthcare sector, has partnered with Shilpa Biologicals Pvt. Ltd. This strategic licensing agreement aims to expand the availability of biosimilars, making them accessible to a larger patient base in the region.

The Agreement Details

Announced on February 25, 2026, this collaboration will see SteinCares obtaining exclusive rights for the registration, marketing, and distribution of a new biosimilar product throughout Latin America. Shilpa Biologicals will be responsible for developing and manufacturing this biosimilar from their facilities in Dharwad, India. This partnership signifies a crucial step towards improving healthcare accessibility and efficiency in Latin America by leveraging Shilpa's expertise in biological product development combined with SteinCares' strong market presence.

Importance of Biosimilars

Biosimilars are biological medical products highly similar to existing, approved reference products. They play a pivotal role in reducing healthcare costs and enhancing treatment options available to patients, particularly in regions where access to innovative therapies has been limited. This partnership is set to not only broaden the scope of biosimilars in Latin America but also strengthen SteinCares' position as a leader in this vital area of medicine.

Mitchell Waserstein, CEO of SteinCares, expressed enthusiasm for the collaboration, emphasizing its importance in fulfilling the growing need for affordable treatment options. He stated, "By partnering with Shilpa Biologicals, we aim to introduce this biosimilar to the Latin American market and reinforce our role as a strategic partner for global biopharmaceutical companies looking to enter complex healthcare markets."

A Global Standards Approach

With over 45 years of experience, SteinCares is noted for its integrated platform that facilitates the efficient delivery of biosimilars across 30 countries in Latin America. The collaboration with Shilpa Biologicals will enhance this initiative by ensuring that high-quality manufacturing standards are met. Dr. Sridevi Khambhampaty, CEO of Shilpa Biologicals, added, "Entering the Latin American market is a significant milestone for us, and we believe that this partnership will create substantial value for patients and healthcare systems alike, while further expanding our biosimilars' footprint in key international markets."

Moving Forward

This partnership not only marks the introduction of a new biosimilar but also sets the stage for future collaborations between the two companies. Both SteinCares and Shilpa Biologicals are committed to fostering long-term international licensing partnerships that can benefit patients worldwide.

As this initiative unfolds, it will pave the way for enhancing medical care in Latin America, providing patients with access to crucial therapies that were previously out of reach. This collaboration showcases a promising future for the biopharmaceutical sector in the region, underpinned by innovation, collaboration, and a shared commitment to affordable healthcare.

In conclusion, the strategic partnership between SteinCares and Shilpa Biologicals serves as a testament to the potential of collaborative efforts in expanding healthcare access and improving patient outcomes in Latin America.